Page last updated: 2024-12-07

2,3-dihydroxybenzaldehyde

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,3-Dihydroxybenzaldehyde, also known as 2,3-dihydroxybenzoic aldehyde, is a naturally occurring compound found in various plants. Its synthesis can be achieved through several methods, including the oxidation of 2,3-dihydroxytoluene or the formylation of 2,3-dihydroxybenzene. Studies have shown that 2,3-dihydroxybenzaldehyde exhibits a range of biological activities, including antioxidant, anti-inflammatory, and antimicrobial properties. Its antioxidant effects are attributed to its ability to scavenge free radicals, while its anti-inflammatory properties are linked to its inhibition of pro-inflammatory enzymes. The antimicrobial activity of 2,3-dihydroxybenzaldehyde has been demonstrated against various bacteria and fungi. These activities have led to research exploring its potential applications in pharmaceutical, food, and cosmetic industries. 2,3-dihydroxybenzaldehyde is also a precursor for the synthesis of other valuable compounds, including the flavonoid quercetin. The compound is studied extensively for its potential in developing new drugs and therapeutic agents, particularly in areas like cancer treatment and neurodegenerative diseases. '

dihydroxybenzaldehyde : Any member of the class of benzaldehydes in which the phenyl ring is substituted by two hydroxy groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID90579
CHEMBL ID491995
CHEBI ID50197
SCHEMBL ID36440
MeSH IDM0183941

Synonyms (47)

Synonym
AE-641/30608014
CHEBI:50197 ,
5,6-dihydroxybenzaldehyde
inchi=1/c7h6o3/c8-4-5-2-1-3-6(9)7(5)10/h1-4,9-10
2,3-dihydroxybenzaldehyde
benzaldehyde, 2,3-dihydroxy-
nsc-146456
nsc146456
o-pyrocatechualdehyde
24677-78-9
2,3-dihydroxybenzaldehyde, 97%
FT-0656682
D1478
CHEMBL491995
AKOS000119466
BBL000528
23a ,
gp9hde43le ,
unii-gp9hde43le
einecs 246-398-1
nsc 146456
A817431
STK902088
FT-0609668
3-formyl-1,2-benzenediol
us8614253, .3-75
bdbm111044
SCHEMBL36440
2,3-dihydroxy-benzaldehyde
2,3-dihydroxy benzaldehyde
W-107289
benzaldehyde, dihydroxy-
AC-24170
mfcd00003324
DTXSID90179411
CS-W007479
SY030837
dihydroxybenzaldehyde
o-pyrocatechualdehyde;benzaldehyde, 2,3-dihydroxy-
BCP25752
Q27104753
AS-14413
1,2-dihydroxy-3-formylbenzene
3-hydroxysalicylaldehyde
dihydroxybenzaldehyde, 2,3-
EN300-17250
Z56899185
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
dihydroxybenzaldehydeAny member of the class of benzaldehydes in which the phenyl ring is substituted by two hydroxy groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID1291713Protective activity against Naja kaouthia venom-induced mortality in Swiss albino mouse at 100 mmol, iv preincubated with venom for 1 hr followed by administration to mouse measured after 24 hrs relative to untreated control2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291712Protective activity against Naja kaouthia venom-induced mortality in Swiss albino mouse at 100 mmol, iv by measuring venom LD50 preincubated with venom for 1 hr followed by administration to mouse measured after 24 hrs (Rvb = 2.82 ug)2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291722Protective activity against Daboia russellii venom-induced hemorrhage in Swiss albino mouse at 100 mmol, iv assessed as hemorhagic lesion administered immediately after venom injection measured after 24 hrs relative to untreated control2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID338748Inhibition of phosphatidylinositol 4-kinase in human A431 cell membrane by liquid scintillation counting
AID1291715Protective activity against Daboia russellii venom-induced hemorrhage in intradermally dosed Swiss albino mouse at 100 mmol assessed as hemorhagic lesion preincubated with venom for 1 hr followed by administration to mouse measured after 24 hrs relative t2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291717Protective activity against Daboia russellii venom-induced mortality in Swiss albino mouse at 100 mmol, iv by measuring venom LD50 administered immediately after venom injection measured after 24 hrs (Rvb = 2.28ug)2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291719Protective activity against Naja kaouthia venom-induced mortality in Swiss albino mouse at 100 mmol, iv by measuring venom LD50 administered immediately after venom injection measured after 24 hrs (Rvb = 2.82 ug)2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291714Protective activity against Daboia russellii venom-induced hemorrhage in intradermally dosed Swiss albino mouse at 100 mmol assessed as hemorhagic lesion by measuring minimal hemolytic dose preincubated with venom for 1 hr followed by administration to mo2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291711Protective activity against Daboia russellii venom-induced mortality in Swiss albino mouse at 100 mmol, iv preincubated with venom for 1 hr followed by administration to mouse measured after 24 hrs relative to untreated control2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291716Lipophilicity, log P of compound2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291710Protective activity against Daboia russellii venom-induced mortality by measuring venom LD50 in Swiss albino mouse at 100 mmol, iv preincubated with venom for 1 hr followed by administration to mouse measured after 24 hrs (Rvb = 2.28 ug)2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291721Protective activity against Daboia russellii venom-induced hemorrhage in Swiss albino mouse at 100 mmol, iv assessed as hemorhagic lesion by measuring minimal hemolytic dose administered immediately after venom injection measured after 24 hrs (Rvb =5 ug)2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (23.08)18.2507
2000's6 (46.15)29.6817
2010's4 (30.77)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.00

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.00 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.00)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]